Most importantly, the combined treatment resulted in an improved enrichment of tumor antigen-specific CD8 T cells and NK cells at the tumor site, associated with better tumor inhibition against tumors co-expressing HER2 and OVA (12). Here, CD8A is linked to neoplasm.